Sandbox: Langerhans: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 23: Line 23:
|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Gender'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:* Males are associated with a worse prognosis when compared to females.
|-


 
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Organ involvement'''|| style="padding: 5px 5px; background: #F5F5F5;"|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Performance status'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:* Patient's poor [[performance status]] is associated with a worse prognosis.
:* Patient's poor [[performance status]] is associated with a worse prognosis.
|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Stage'''|| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Response to treatment'''|| style="padding: 5px 5px; background: #F5F5F5;" |
:*Binet stages B and C or Rai stages 2-4 are associated with a worse prognosis.
:*Binet stages B and C or Rai stages 2-4 are associated with a worse prognosis.


|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte doubling time'''|| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Cellular markers'''|| style="padding: 5px 5px; background: #F5F5F5;" |
:*A rapid [[lymphocyte]] doubling time is associated with a worse prognosis.
:*A rapid [[lymphocyte]] doubling time is associated with a worse prognosis.


|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Genetic mutations'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:*Deletion of [[chromosome 17]] short arm and [[chromosome 11]] long arm are associated with a worse prognosis.
|-
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Prolymphocytes percent'''|| style="padding: 5px 5px; background: #F5F5F5;" |
:*An increased percentage of [[prolymphocyte]]s is associated with a worse prongnosis.
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Histological analysis'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:*Diffuse [[histology]] on [[bone marrow aspiration]] is associated with a worse prognosis.
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lactate dehydrogenase (LDH) level'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:*Elevated level of [[LDH]] is associated with a worse prognosis.
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''β2-microglobulin level '''|| style="padding: 5px 5px; background: #F5F5F5;"|
:*Elevated level of β2-microglobulin level is associated with a worse prognosis.
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte surface markers'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:*Over expression of [[CD38]] is associated with a worse prognosis.
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Immunoglobulin (Ig)VH gene'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:*The absence of IgVH [[gene]] mutation is associated with a worse prognosis.
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Membrane-bound proteins'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:*The expression of zeta-chain-associated protein kinase 70 (ZAP) is associated with a worse prognosis.
|}
|}

Revision as of 16:25, 4 February 2016

  • Several cellular markers have been associated with poor disease prognosis, including expression of certain metalloproteinases and gelosin, a regulatory protein involved in the disassembly of actin microfilaments.41 Other factors for poor prognosis include extensive organ involvement and younger patient age at diagnosis.8 Younger age at diagnosis is associated with multisystem disease.

Prognostic factors in LCH have been identified and can be categorized as follows:

   Age at diagnosis: Although age younger than 2 years was once thought to portend a worse prognosis, data from the LCH-II study showed that patients aged 2 years or younger without high-risk organ involvement had the same response to therapy as older patients.[16] By contrast, the OS was poorer in neonates with risk-organ involvement compared with infants and children with the same extent of disease when patients were treated for only 6 months.[16]
   Response to treatment: Response to therapy at 6 to 12 weeks has been shown to be a more important prognostic factor than age.[19] The overall response to therapy is influenced by the duration and intensity of treatment.[15,16]
   Organ involvement: Involvement of craniofacial bones including orbital, mastoid, and temporal bones is associated with an increased risk of diabetes insipidus and an increased frequency of anterior pituitary hormone deficiencies and neurologic problems. (Refer to the Endocrine system subsection in the Multisystem Disease Presentation section of this summary for more information on diabetes insipidus.)


  • The table below lists prognostic factors for Langerhans cell histiocytosis patients:
Prognostic Factor Description
Age
  • Older age at the time of diagnosis is associated with a worse prognosis.
Organ involvement
Response to treatment
  • Binet stages B and C or Rai stages 2-4 are associated with a worse prognosis.
Cellular markers
  • A rapid lymphocyte doubling time is associated with a worse prognosis.